Related Experiment Videos
Hepatic Selenoprotein P Impairs Bone Formation via Osteoblastic IGF-1 Resistance
Kiyo-Aki Ishii1,2, Hiroaki Takayama1,3, Cynthia M Galicia-Medina1
1Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, 920-8640, Japan.
Abstract:
Bone fragility is increasingly recognized as a complication of metabolic dysfunction, but endocrine mechanisms linking hepatic stress to impaired bone formation remain incompletely defined. We tested whether selenoprotein P, a hepatokine elevated in metabolic disease, suppresses osteoblast function and skeletal integrity. In mice fed a high-fat, high-sucrose diet, whole-body Selenop deficiency preserved trabecular bone mass, bone formation, bone stiffness, and cortical bone defect repair. Hepatocyte-specific Selenop deficiency also preserved trabecular bone mass. Histomorphometry showed that selenoprotein P primarily suppressed osteoblast activation without materially altering osteoclast indices. In calvaria-derived osteoblast cultures, purified human plasma-derived selenoprotein P inhibited IGF-1-induced phosphorylation of IGF-1 receptor, IRS-1, PI3K, PDK1, and Akt, reduced alkaline phosphatase activity, matrix mineralization, and osteogenic gene expression, and blunted receptor-proximal ROS generation. LRP1 was the predominant candidate receptor during osteogenic differentiation. Osteoblast cultures derived from Osx-Cre/+ Lrp1fl/fl mice showed reduced cell-associated human selenoprotein P, and the inhibitory effects of selenoprotein P on IGF-1 signaling and osteoblast maturation were absent in these cultures. In vivo, pharmacologic blockade of IGF-1 receptor signaling eliminated the skeletal protection conferred by Selenop deficiency, supporting a requirement for intact IGF-1 receptor signaling in this pathway. In a cross-sectional analysis of a general population cohort, serum selenoprotein P was not significantly associated with OSI across the full cohort, whereas exploratory analyses in the highest quintile suggested an inverse association between high circulating selenoprotein P and bone mass. Together, these findings identify hepatic selenoprotein P as a negative regulator of bone formation and define a hepato-osteogenic reductive stress axis that links metabolic stress to impaired skeletal integrity.
Related Concept Videos
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...